We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Noninvasive Technology Detects Rare Cancer Cells in Blood

By LabMedica International staff writers
Posted on 10 Jun 2024

Historically, analyzing circulating tumor cells (CTCs) required invasive methods like blood draws, which often missed rare CTCs or multicellular CTC clusters (CTCCs) known for their high metastatic potential. More...

Now, a groundbreaking technology offers a new way for researchers to monitor and understand the spread of cancer within the body.

A collaborative effort between researchers at Northeastern University (Boston, MA, USA) and Dartmouth College (Hanover, NH, USA) has led to the development of an innovative device known as "diffuse in vivo flow cytometry" (DiFC). This technology facilitates the noninvasive detection and counting of rare cancer cells circulating in the bloodstream. By utilizing highly scattered light to probe large blood vessels, DiFC overcomes the shortcomings of traditional tests to enable the noninvasive analysis of larger peripheral blood volumes and detection of rare cancer cells. The team’s pioneering two-color DiFC system can simultaneously identify two distinct populations of cancer cell in real time within small animals, paving the way for deeper insights into cancer evolution and treatment responses by studying various cancer cell subpopulations in the same subject.

The versatility of this two-color DiFC system was demonstrated through experiments on tissue-mimicking flow phantoms and mice afflicted with multiple myeloma. By effectively distinguishing cancer cells marked by green fluorescent protein (GFP) and tdTomato, it was possible to observe the dynamics of cancer spread in real time. Notably, most detected CTCCs exhibited single fluorescent proteins, shedding light on the heterogeneity of cancer cell populations. The implications of this technology are significant as it offers the potential to simultaneously track various subpopulations of cancer cells, providing critical insights into tumor growth and therapeutic responses. This paves the way for more refined and individualized treatment options, moving closer to effectively managing cancer. While the battle against cancer is complex, advancements like DiFC provide the tools essential for meeting this challenge. As this technology evolves, it promises to lead to more effective cancer therapies and a future where cancer may no longer be a life-threatening condition. 

Related Links:
Northeastern University
Dartmouth College


New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Gold Member
Aspiration System
VACUSAFE
New
Manual Pipetting Aid
Pipette Controllers macro
New
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: The GenoPredict assay from Predicta Biosciences is available to Tempus Life Sciences partners to support exploratory research and clinical development programs (photo courtesy of Shutterstock)

Partnership Expands Ultrasensitive WGS Assay for for Hematologic Malignancies and MRD Monitoring

Tempus AI and Predicta Biosciences announced the commercial expansion of a co-branded whole‑genome sequencing assay GenoPredicta, which is intended for comprehensive genomic characterization of hematologic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.